title: Postoperative therapy in head and neck cancer: state of the art, risk subset, prognosis and unsolved questions.
abstract: Head and neck cancer may be easily controlled at early stages, but resectable locally advanced disease often relapses at T and N sites. Therefore, adequate adjuvant treatment is of crucial importance for improving local control and/or survival. Unfortunately, little data are available on the adjuvant setting. Adjuvant radiotherapy is regarded as a standard approach for patients with locally advanced radically resected head and neck cancer, while postoperative chemotherapy alone cannot be considered outside of clinical trials. However, chemoradiotherapy is widely considered superior to radiotherapy in patients at a high risk of relapse and may be considered the standard treatment in this population. In this respect, in the last few decades, there has been a growing interest due to the emerging data on both tumor biology and clinical trials. Several pathological and molecular factors, affecting behavior and head and neck cancer prognosis, could allow for a better selection of postoperative treatment. More recently, new prognostic and predictive factors were identified, including biomolecular aspects, human papillomavirus infection and lifestyle. The integration of these new factors deserves dedicated clinical studies, but the available knowledge already allows some deductive hypotheses. We performed a review of the literature to analyze the role of therapy in the postoperative setting and to discuss both the possibility of a different approach to each class of risk and the unsolved question for which randomized trials are warranted.
authors.affiliation: Department of Oncology, AOU G. Martino Messina University, Messina, Italy. nerinadenaro@gmail.com
authors.forename: Nerina
authors.initials: N
authors.lastname: Denaro
authors.forename: Elvio G
authors.initials: EG
authors.lastname: Russi
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Adamo
authors.forename: Ida
authors.initials: I
authors.lastname: Colantonio
authors.forename: Marco C
authors.initials: MC
authors.lastname: Merlano
mesh_terms: D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D006258:Head and Neck Neoplasms / Q000628:therapy*; D006801:Humans; D011184:Postoperative Period; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D012307:Risk Factors